IHH Healthcare Q2 FY2026 Shows Robust Revenue Growth Amid Pressures

IHH Healthcare Accelerates Growth Amid Regional Shifts and Complex Global Headwinds

IHH Healthcare demonstrated robust scale in Q2 FY2026, reporting a 12% increase in revenue to RM 7.0 billion and a 36% surge in PATMI (excluding exceptional items) to RM 569 million. This performance supports an interim dividend of 5.5 sen per share, yet the headline figures mask significant regional variance and currency-driven distortion. Investors must weigh strong volume gains in emerging markets against structural shifts in high-margin hubs and an impending RM 5.2 billion legal judgment.

Turkiye and Europe Lead the Charge Against Hyperinflation

The Turkiye and Europe segment remains a primary growth driver, delivering 20% revenue growth and a 32% EBITDA increase for the quarter. These results were underpinned by aggressive case-mix optimization and price adjustments designed to offset severe local inflation. The Group is effectively utilizing operating leverage in this region to maintain margins despite a volatile macroeconomic backdrop.

Reported profitability in this segment is significantly impacted by MFRS 129 accounting for hyperinflationary economies. The Group recognized a net monetary gain of RM 136 million, which bolstered the reported Profit Before Tax. Investors should note that this gain is a non-cash accounting adjustment and does not represent a corresponding increase in operational cash flow.

“As a uniquely diversified, multinational network, IHH is able to navigate uncertainties through targeted strategies for each of our 10 countries, while ensuring Group-level synergies on cost, systems and operational excellence.” — Dr. Prem Kumar Nair, Group CEO

The Surprising Admission Slump in Singapore

Singapore, traditionally a high-margin anchor for the Group, faced distinct headwinds with a 6% decline in inpatient admissions and a 10% drop in reported revenue. This downturn reflects a structural shift as local patients increasingly utilize public healthcare services. Furthermore, Middle East tensions continue to dampen demand from high-value medical travelers who typically seek complex care in this hub.

Financial reporting for Singapore was further pressured by significant FX translation headwinds. The Ringgit Malaysia strengthened against the Singapore Dollar, with the exchange rate shifting from 3.30 to 3.11 year-over-year. This currency movement exacerbated the reported revenue decline for Malaysian stakeholders, making the hub’s stabilization a priority for the second half of the year.

India Emerges as a High Volume Growth Engine

India served as a volume powerhouse in Q2 FY2026, with inpatient admissions surging 14% to nearly 95,000 cases. Revenue per admission also grew by 5%, driven by a more complex case mix and the successful integration of acquisitions like TMI Healthcare. This operational momentum demonstrates the resilient underlying demand for private healthcare in the Indian market.

Despite these strong volumes, India’s reported revenue showed a -1% variance because the strengthening Ringgit masked the underlying growth. Operating margins in the region also faced pressure from the new labor code effective since November 2025, which has increased staff costs. This remains a “volume-strong but currency-weak” story where operational excellence is battling FX translation and regulatory cost hurdles.

Regional Performance Snapshot

The following table visualizes the variance in reported performance across major operating segments for Q2 FY2026. Note that “Core” constant currency revenue growth for the Group was 19%, significantly higher than the “Reported” 12% due to Ringgit strength.

Litigation Milestones and the Five Billion Ringgit Question

A critical legal milestone is approaching regarding the tort claim filed by NTK against Daiichi in the Tokyo District Court. The claim involves alleged unlawful interference with trade and defamation related to the Fortis and Malar open offers. NTK is seeking a massive INR 109.3 billion, which translates to approximately RM 5.2 billion.

The court has concluded preparatory proceedings and is scheduled to announce its judgment on September 10, 2026. This date is paramount for investors as the outcome could materially impact IHH’s balance sheet and reputation. Given the scale of the claim relative to annual earnings, the judgment represents a significant “binary risk” for the stock.

Outlook

IHH Healthcare is maintaining its trajectory toward a double-digit ROE target by 2028, supported by technological enablement and operational standardization. The 5.5 sen interim dividend signals management’s confidence in the Group’s cash-generating capabilities. However, investors must remain mindful of persistent wage inflation and the continued impact of Ringgit volatility on foreign earnings.

The Group’s diversified footprint provides a natural hedge, but the interplay between hyperinflationary pricing and currency translation will continue to complicate the financial narrative. As we move into the next quarter, we recommend focusing on these three specific indicators:

• The outcome of the RM 5.2 billion Japan litigation on September 10.
• The sustainability of price adjustments in Turkiye relative to the non-cash MFRS 129 gains.
• The stabilization of patient volumes and medical traveler demand in the Singapore market.

Related stories: Camsing Healthcare Faces Severe Going Concern Risks As Q2 FY2027 Deficit Deepens